<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">115219</article-id><article-id pub-id-type="doi">10.17816/onco115219</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Clinical investigations</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">High expression of CD8+ T-lymphocytes in the peritumoral zone of renal cancer as a factor of unfavorable prognosis</article-title><trans-title-group xml:lang="ru"><trans-title>Высокая экспрессия CD8+ Т-лимфоцитов в перитуморозной зоне рака почки как фактор неблагоприятного прогноза</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9097-6733</contrib-id><contrib-id contrib-id-type="spin">2375-1427</contrib-id><name-alternatives><name xml:lang="en"><surname>Bobrov</surname><given-names>Igor P.</given-names></name><name xml:lang="ru"><surname>Бобров</surname><given-names>Игорь Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>ig.bobrov2010@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1080-5294</contrib-id><contrib-id contrib-id-type="spin">1161-8387</contrib-id><name-alternatives><name xml:lang="en"><surname>Lazarev</surname><given-names>Alexander  F.</given-names></name><name xml:lang="ru"><surname>Лазарев</surname><given-names>Александр Федорович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>lazarev@arzs.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7292-4996</contrib-id><contrib-id contrib-id-type="spin">3773-8785</contrib-id><name-alternatives><name xml:lang="en"><surname>Cherdantseva</surname><given-names>Tatyana  M.</given-names></name><name xml:lang="ru"><surname>Черданцева</surname><given-names>Татьяна Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Associate Professor</p></bio><bio xml:lang="ru"><p>д.м.н., доцент</p></bio><email>cherdan.morf@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9889-9517</contrib-id><name-alternatives><name xml:lang="en"><surname>Klimachev</surname><given-names>Ilya  V.</given-names></name><name xml:lang="ru"><surname>Климачев</surname><given-names>Илья Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><bio xml:lang="ru"><p>врач-патологоанатом</p></bio><email>k0222@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1586-252X</contrib-id><contrib-id contrib-id-type="spin">8120-3059</contrib-id><name-alternatives><name xml:lang="en"><surname>Klimachev</surname><given-names>Vladimir  V.</given-names></name><name xml:lang="ru"><surname>Климачев</surname><given-names>Владимир Васильевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>pathology_agmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3256-6706</contrib-id><name-alternatives><name xml:lang="en"><surname>Myadelets</surname><given-names>Mikhail  N.</given-names></name><name xml:lang="ru"><surname>Мяделец</surname><given-names>Михаил Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>pathology_agmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2477-4687</contrib-id><contrib-id contrib-id-type="spin">7516-0963</contrib-id><name-alternatives><name xml:lang="en"><surname>Lepilov</surname><given-names>Alexander  V.</given-names></name><name xml:lang="ru"><surname>Лепилов</surname><given-names>Александр Васильевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>lepilov@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7677-4622</contrib-id><contrib-id contrib-id-type="spin">2804-0011</contrib-id><name-alternatives><name xml:lang="en"><surname>Dolgatov</surname><given-names>Andrey  Yu.</given-names></name><name xml:lang="ru"><surname>Долгатов</surname><given-names>Андрей Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Associate Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>adolgatov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0094-4656</contrib-id><name-alternatives><name xml:lang="en"><surname>Korsikov</surname><given-names>Nikolay  A.</given-names></name><name xml:lang="ru"><surname>Корсиков</surname><given-names>Николай Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nikkor94knaagmu@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6678-4472</contrib-id><name-alternatives><name xml:lang="en"><surname>Dolgatova</surname><given-names>Elena  S.</given-names></name><name xml:lang="ru"><surname>Долгатова</surname><given-names>Елена Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>esdol82@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2614-8690</contrib-id><contrib-id contrib-id-type="spin">3310-1175</contrib-id><name-alternatives><name xml:lang="en"><surname>Lushnikova</surname><given-names>Elena  L.</given-names></name><name xml:lang="ru"><surname>Лушникова</surname><given-names>Елена Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>pathol@inbox.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9614-592X</contrib-id><contrib-id contrib-id-type="spin">3630-9977</contrib-id><name-alternatives><name xml:lang="en"><surname>Bakarev</surname><given-names>Maxim  A.</given-names></name><name xml:lang="ru"><surname>Бакарев</surname><given-names>Максим Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>pathol@inbox.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Altai State Medical University</institution></aff><aff><institution xml:lang="ru">Алтайский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Ryazan State Medical University named after Academician I.P. Pavlov</institution></aff><aff><institution xml:lang="ru">Рязанский государственный медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine</institution></aff><aff><institution xml:lang="ru">Институт молекулярной патологии и патоморфологии Федерального исследовательского центра фундаментальной и трансляционной медицины</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-10-14" publication-format="electronic"><day>14</day><month>10</month><year>2022</year></pub-date><volume>27</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>97</fpage><lpage>105</lpage><history><date date-type="received" iso-8601-date="2022-12-07"><day>07</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-03"><day>03</day><month>04</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Эко-Вектор</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-10-14"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/115219">https://rjonco.com/1028-9984/article/view/115219</self-uri><abstract xml:lang="en"><p><bold><italic>AIM:</italic></bold> To evaluate the prognostic value of quantitative CD8+ T-lymphocyte counts in the peritumorotic zone of renal cell cancer.</p> <p><bold><italic>MATERIAL AND METHODS:</italic></bold> The material of 74 patients after operative treatment for renal cell carcinoma with complete 5-year follow-up was retrospectively analyzed. Of the 74 patients, 56 were alive by the 5-year follow-up, and 18 had died of cancer. After immunohistochemical staining, CD8+ T-lymphocyte distribution density in the peritumorotic zone of carcinomas was determined in 3 representative fields of view at ×400 magnification and correlated with the clinicopathological characteristics of neoplasms and overall 5-year patient survival rate.</p> <p><bold><italic>RESULTS:</italic></bold> The high level of CD8+ T-lymphocyte infiltration in the peritumoral zone of carcinomas was seen in stages III–IV of the disease (<italic>p</italic>=0.0000001), in tumors &gt;7 cm (<italic>p</italic>=0.0000001), in Fuhrman grade III–IV anaplasia (<italic>p</italic>=0.001), in metastases (<italic>p</italic>=0.0000001) and in the shorter total survival rate of patients (<italic>p</italic>=0.0003). High CD8+ T-lymphocyte count was also observed in men (<italic>p</italic>=0.001) and in cases of unclassified cancer.</p> <p><bold><italic>CONCLUSION:</italic></bold> In the light of the need to search for new prognostic criteria in renal cancer, we conclude that a high level of peritumorous zone infiltration by CD8+ T-lymphocytes is an unfavorable prognostic factor. Assessment of peritumorous zone infiltration by CD8+ T-lymphocytes may serve as an additional prognostic factor in renal cell carcinoma.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель </bold>— оценка прогностического значения количественного подсчёта CD8+ Т-лимфоцитов в перитуморозной зоне почечно-клеточного рака.</p> <p><bold>Материал и методы.</bold> Ретроспективно проанализирован материал 74 пациентов после оперативного лечения по поводу почечно-клеточной карциномы с полным 5-летним наблюдением. 56 из 74 пациентов к 5-летнему сроку наблюдения были живы, а 18 умерли от рака. После иммуногистохимического окрашивания определяли плотность распределения CD8+ Т-лимфоцитов в перитуморозной зоне карцином в трёх репрезентативных полях зрения при увеличении ×400 и сопоставляли полученные данные с клинико-патологическими характеристиками новообразований и общей 5-летней выживаемостью пациентов.</p> <p><bold>Результаты. </bold>Высокий уровень инфильтрации перитуморозной зоны карцином CD8+ Т-лимфоцитами отмечен при III–IV стадиях заболевания (<italic>p</italic>=0,0000001), в опухолях &gt;7 см (<italic>p</italic>=0,0000001), при III–IV степенях анаплазии по Fuhrman (<italic>p</italic>=0,001), при наличии метастазов (<italic>p</italic>=0,0000001) и при более короткой общей выживаемости пациентов (<italic>p</italic>=0,0003). Установлено также высокое содержание CD8+ Т-лимфоцитов у мужчин (<italic>p</italic>=0,001) и в случаях неклассифицируемого рака.</p> <p><bold>Заключение.</bold> В свете необходимости поиска новых прогностических критериев при раке почки заключаем, что высокий уровень инфильтрации перитуморозной зоны CD8+ Т-лимфоцитами является неблагоприятным фактором прогноза. Оценка инфильтрации перитуморозной зоны рака почки CD8+ Т-лимфоцитами может служить дополнительным прогностическим фактором при почечно-клеточной карциноме.</p></trans-abstract><kwd-group xml:lang="en"><kwd>renal cancer</kwd><kwd>peritumoral zone</kwd><kwd>CD8+ T-lymphocytes</kwd><kwd>prognostic factors</kwd><kwd>overall survival analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак почки</kwd><kwd>околоопухолевая зона</kwd><kwd>CD8+ T-лимфоциты</kwd><kwd>факторы прогноза</kwd><kwd>анализ общей выживаемости</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Bobrov IP, Lazarev AF, Cherdantseva TM, et al. Prognostic value of quantitayive assessment of macrophage content (CD68+) in the Peritumoral zone of clear cell renal carcinoma. Russian Journal of Oncology. 2021;26(2):49–56. (In Russ). doi: https://doi.org/10.17816/1028-9984-2021-26-2-49-56</mixed-citation><mixed-citation xml:lang="ru">Бобров И.П., Лазарев А.Ф., Черданцева Т.М., и др. Прогностическое значение количественной оценки содержания макрофагов (CD68+) в перитуморозной зоне светлоклеточного рака почки // Российский онкологический журнал. 2021. Т. 26, № 2. С. 49–56. doi: 10.17816/1028-9984-2021-26-2-49-56</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Bobrov IP, Cherdantseva TM, Dolgatova ES, et al. Predictive value of quantitative assessment B-lymphocytes the peritumorous zone in renal cell carcinoma. Modern Problems of Science and Education. 2021;2:172–179. (In Russ). doi: 10.17513/spno.30739</mixed-citation><mixed-citation xml:lang="ru">Бобров И.П., Черданцева Т.М., Долгатова Е.С., и др. Прогностическое значение количественной оценки B-лимфоцитов в перитуморозной зоне рака почки // Современные проблемы науки и образования. 2021. № 2. С. 172–179. doi: 10.17513/spno.30739</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Bobrov IP, Klimachev IV, Myadelez MN, et al. Prognostic value of quantitative assessment of mast cell number (CD117+) in the peritumoral zone of clear cell renal carcinoma. Bulletin of Scientific Conferences. 2020;(4-2):20–22. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Бобров И.П., Климачев И.В., Мяделец М.Н., и др. Прогностическое значение количественной оценки числа тучных клеток (CD117+) в перитуморозной зоне светлоклеточного рака почки // Вестник научных конференций. 2020. № 4-2. С. 20–22.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Cherdantseva TM, Bobrov IP, Avdalyan AM, et al. Mast cells in renal cancer: clinical morphological correlations and prognosis. Bulletin of Experimental Biology and Medicine. 2017;163(6):768–772. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Черданцева Т.М., Бобров И.П., Авдалян А.М., и др. Тучные клетки при раке почки: клинико-морфологические взаимосвязи и прогноз // Бюллетень экспериментальной биологии и медицины. 2017. Т. 163, № 6. С. 768–773.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Kumar V, Abbas AK, Aster KC. Robbins and cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2015.</mixed-citation><mixed-citation xml:lang="ru">Kumar V., Abbas A.K., Aster K.C. Robbins and cotran pathologic basis of disease. Philadelphia : Elsevier Saunders, 2015.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Danilova NV, Komyakov VM, Chayka AV, et al. Haracteristics of theimmune microenvironment of the normal membrane of the peritumoral area is an additional independent prognostic factor in gastric cancer. Siberian Journal of oncology. 2021;20(1):74–86. (In Russ). doi: 10.21294/1814-4861-2021-20-1-74-86</mixed-citation><mixed-citation xml:lang="ru">Данилова Н.В., Хомяков В.М., Чайка А.В., и др. Характеристики иммунного микроокружения нормальной слизистой оболочки перитуморозной области — дополнительный прогностический фактор при раке желудка // Сибирский онкологический журнал. 2021. Т. 20, № 1. С. 74–86. doi: 10.21294/1814-4861-2021-20-1-74-86</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Ma HY, Liu XZ, Liang CM. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World J Gastroenterol. 2016;22(29):6619–6628. doi: 10.3748/wjg.v22.i29.6619</mixed-citation><mixed-citation xml:lang="ru">Ma H.Y., Liu X.Z., Liang C.M. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer // World J Gastroenterol. 2016. Vol. 22, N 29. P. 6619–6628. doi: 10.3748/wjg.v22.i29.6619</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Sawayama H, Ishimoto T, Baba H. Microenvironment in the pathogenesis of gastric cancer metastasis. J Cancer Metastasis Treat. 2018;4:10. doi: 10.20517/2394-4722.2017.79</mixed-citation><mixed-citation xml:lang="ru">Sawayama H., Ishimoto T., Baba H. Microenvironment in the pathogenesis of gastric cancer metastasis // J Cancer Metastasis Treat. 2018. Vol. 4. P. 10. doi: 10.20517/2394-4722.2017.79</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Sofopoulos M, Fortis SP, Vaxevanis CK, et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother. 2019;68(11):1733–1745. doi: 10.1007/s00262-019-02407-8</mixed-citation><mixed-citation xml:lang="ru">Sofopoulos M., Fortis S.P., Vaxevanis C.K., et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer // Cancer Immunol Immunother. 2019. Vol. 68, N 11. P. 1733–1745. doi: 10.1007/s00262-019-02407-8</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Hu WH, Miyai K, Cajas-Monson LC, et al. Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. J Surg Oncol. 2015;112(4):421–426. doi: 10.1002/jso.23998</mixed-citation><mixed-citation xml:lang="ru">Hu W.H., Miyai K., Cajas-Monson L.C., et al. Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma // J Surg Oncol. 2015. Vol. 112, N 4. P. 421–426. doi: 10.1002/jso.23998</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Giuşcă SE, Wierzbicki PM, Amălinei C, et al. Comparative analysis of CD4 and CD8 lymphocytes — evidences for different distribution in primary and secondary liver tumors. Folia Histochem Cytobiol. 2015;53(3):272–281. doi: 10.5603/fhc.a2015.0027</mixed-citation><mixed-citation xml:lang="ru">Giuşcă S.E., Wierzbicki P.M., Amălinei C., et al. Comparative analysis of CD4 and CD8 lymphocytes — evidences for different distribution in primary and secondary liver tumors // Folia Histochem Cytobiol. 2015. Vol. 53, N 3. P. 272–281. doi: 10.5603/fhc.a2015.0027</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Funada Y, Noguchi T, Kikuchi R, et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10(2):309–313.</mixed-citation><mixed-citation xml:lang="ru">Funada Y., Noguchi T., Kikuchi R., et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer // Oncol Rep. 2003. Vol. 10, N 2. P. 309–313.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Pyo JS, Kwan SB, Young LH, et al. Prognostic implications of Intratumoral and peritumoral infiltrating lymphocytes in pancreatic ductal adenocarcinoma. Curr Oncol. 2021;28(6):4367–4376. doi: 10.3390/curroncol28060371</mixed-citation><mixed-citation xml:lang="ru">Pyo J.S., Kwan S.B., Young L.H., et al. Prognostic implications of Intratumoral and peritumoral infiltrating lymphocytes in pancreatic ductal adenocarcinoma // Curr Oncol. 2021. Vol. 28, N 6. P. 4367–4376. doi: 10.3390/curroncol28060371</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Blessin NC, Li W, Mandelkow T, et al. Prognostic role proliferating CD+ cytotoxic T-cells in human cancers. Cell Oncol (Dordr). 2021;44(4):793–803. doi: 10.1007/s13402-021-00601-4</mixed-citation><mixed-citation xml:lang="ru">Blessin N.C., Li W., Mandelkow T., et al. Prognostic role proliferating CD+ cytotoxic T cells in human cancers // Cell Oncol (Dordr). 2021. Vol. 44, N 4. P. 793–803. doi: 10.1007/s13402-021-00601-4</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132–5136.</mixed-citation><mixed-citation xml:lang="ru">Nakano O., Sato M., Naito Y., et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity // Cancer Res. 2001 Vol. 61, N 13. P. 5132–5136.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Noessner E, Brech D, Mendler AN, et al. Intratumoral alterations of dendritic-cell differentiation and CD8+ T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. OncoImmunology. 2012;8(1):1451–1453. doi: 10.4161/onci.21356</mixed-citation><mixed-citation xml:lang="ru">Noessner E., Brech D., Mendler A.N., et al. Intratumoral alterations of dendritic-cell differentiation and CD8+ T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma // OncoImmunology. 2012. Vol. 8, N 1. P. 1451–1453. doi: 10.4161/onci.21356</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Giraldo NA, Becht E, Pagès F, et al. Orchestraction and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21(13):3031–3040. doi: 10.1158/1078-0432.CCR-14-2926</mixed-citation><mixed-citation xml:lang="ru">Giraldo N.A., Becht E., Pagès F., et al. Orchestraction and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cagcer // Clin Cancer Res. 2015. Vol. 21, N 13. P. 3031–3040. doi: 10.1158/1078-0432.CCR-14-2926</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Remark R, Alifano M, Cremer I, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013;19(15):4079–4091. doi: 10.1158/1078-0432.CCR-12-3847</mixed-citation><mixed-citation xml:lang="ru">Remark R., Alifano M., Cremer I., et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin // Clin Cancer Res. 2013. Vol. 19, N 15. P. 4079–4091. doi: 10.1158/1078-0432.CCR-12-3847</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Schleypen JS, Baur N, Kammerer R, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res. 2006;12(3 Pt 1):718–725. doi: 10.1158/1078-0432.CCR-05-0857</mixed-citation><mixed-citation xml:lang="ru">Schleypen J.S., Baur N., Kammerer R., et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma // Clin Cancer Res. 2006. Vol. 12, N 3(Pt 1). P. 718–725. doi: 10.1158/1078-0432.CCR-05-0857</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Prinz PU, Mendler AN, Masouris I, et al. High DGK-α and disabled MARK pathways cause dysfunction of human tumour-infiltrating CD8+ T cells that is reversible by pharmacologic intervention. J Immunol. 2012;188(12):5990–6000. doi: 10.4049/jimmunol.1103028</mixed-citation><mixed-citation xml:lang="ru">Prinz P.U., Mendler A.N., Masouris I., et al. Hidh DGK-α and disabled MARK pathways cause dysfunction of human tumour-infiltrating CD8+ T cells that is reversible by pharmacologic intervention // J Immunol. 2012. Vol. 188, N 12. P. 5990–6000. doi: 10.4049/jimmunol.1103028</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Edwards JP, Emens LA. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages. Int Immunopharmacol. 2010;10(10):1220–1228. doi: 10.1016/j.intimp.2010.07.002</mixed-citation><mixed-citation xml:lang="ru">Edwards J.P., Emens L.A. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages // Int Immunopharmacol. 2010. Vol. 10, N 10. P. 1220–1228. doi: 10.1016/j.intimp.2010.07.002</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Cherdantseva TM, Bobrov IP, Klimachev VV, et al. Morphofunctional characterictics of fibroblasts in peritumoral zone of renal cell carcinoma in degrees on malignancy. Russian Journal of Oncology. 2013:18(6):12–16. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Черданцева Т.М., Бобров И.П., Климачев В.В., и др. Морфофункциональная характеристика клеток фибробластического ряда перитуморозной зоны почечно-клеточного рака разной степени злокачественности // Российский онкологический журнал. 2013. Т. 18, № 6. С. 12–16.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Cherdantseva TM, Bobrov IP, Klimachev VV, et al. Histospectrophotometrical and immunohistochemistrical research of renal intratubular neoplasia in peritumourous zone of a renal carcinoma. Сancer Urology. 2012;8(3):18–24. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Черданцева Т.М., Бобров И.П., Климачев В.В., и др. Гистоспектрофотометрическое и иммуногистохимическое исследование ренальной интратубулярной неоплазии в перитуморозной зоне рака почки // Онкоурология. 2012. Т. 8, № 3. С. 18–24.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Cherdantseva TM, Bobrov IP, Klimachev VV, et al. Proliferation and apoptosis of a renal cell in the peritumorous zone. Vestnik of Novosibirsk State University. Series: Biology and Clinical Medicine. 2012;10(3):180–186. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Черданцева Т.М., Бобров И.П., Климачев В.В., и др. Пролиферация и апоптоз почечного эпителия в перитуморозной зоне при раке почки // Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. 2012. Т. 10, № 3. С. 180–186.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Bobrov IP, Cherdantseva TM, Klimachev VV, et al. Morphofunctional activity of nucleolus organizers in renal cancer: relationship with the histological structure of the peritumoral zone. Fundamental Research. 2011;(11):485–490. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Бобров И.П., Черданцева Т.М., Климачев В.В., и др. Морфофункциональная активность ядрышковых организаторов при раке почки: взаимосвязь с гистологическим строением перитуморозной зоны // Фундаментальные исследования. 2011. № 11. С. 485–490.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
